Financial Advantage’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-44,719
Closed -$4.44M 153
2019
Q3
$4.44M Buy
44,719
+260
+0.6% +$24.7K 3.03% 17
2019
Q2
$4.11M Buy
44,459
+541
+1% +$51.4K 2.81% 18
2019
Q1
$4.14M Buy
+43,918
New +$3.84M 2.95% 17
2015
Q1
Sell
-200
Closed -$22K 143
2014
Q4
$22K Hold
200
0.02% 71
2014
Q3
$19K Hold
200
0.02% 78
2014
Q2
$17K Hold
200
0.02% 79
2014
Q1
$14K Sell
200
-256
-56% -$20.3K 0.01% 90
2013
Q4
$39K Buy
456
+256
+128% +$20.3K 0.03% 83
2013
Q3
$15K Hold
200
0.01% 113
2013
Q2
$12K Buy
+200
New +$12K 0.01% 128

Other funds holding CELG

Financial Advantage's CELG Position: Q4 2019 in Review

Financial Advantage sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 44,719 shares — an estimated $4.44M sold.

Financial Advantage first reported a position in CELG in Q2 2013 and held it in 10 quarters. The position peaked at $4.44M in Q3 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Financial Advantage reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Financial Advantage sold 44,719 Celgene Corp shares in Q4 2019, an estimated $4.44M.
  • Financial Advantage first reported a position in Celgene Corp in Q2 2013 and held it in 10 quarters.
  • Financial Advantage's Celgene Corp position peaked at $4.44M in Q3 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Financial Advantage's 13F filing for Q4 2019, filed 31 Jan 2020.